Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues

AIDS Research and Human Retroviruses

Volumn 29, Issue 3, 2013, Pages 592-601

  Chandra, Neelima ^a   Thurman, Andrea Ries ^a   Anderson, Sharon ^a   Cunningham, Tina Duong ^b   Yousefieh, Nazita ^a   Mauck, Christine ^a   Doncel, Gustavo F ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD45 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; HLA DR ANTIGEN; MEDROXYPROGESTERONE ACETATE; T6 ANTIGEN;

ARTICLE; CELL COUNT; CELL DENSITY; CELL POPULATION; CELL PROLIFERATION; COHORT ANALYSIS; DRUG EFFECT; FEMALE; FOLLICULAR PHASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IMMUNOCOMPETENT CELL; LEUKOCYTE ACTIVATION; MACROPHAGE; MENSTRUAL CYCLE; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE; TARGET CELL; VAGINA EPITHELIUM; VAGINA MUCOSA;

ADULT; ANTIGENS, CD; BIOPSY; CELL COUNT; COHORT STUDIES; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; FEMALE; HIV-1; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOCYTES; MEDROXYPROGESTERONE ACETATE; MUCOUS MEMBRANE; PROSPECTIVE STUDIES; RECEPTORS, CCR5; VAGINA;

EID: 84874487530     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0271     Document Type: Article

References (82)

1. UNAIDS. World AIDS Day Report 2011.
2. Kaunitz AM: Long-Acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol 1994;170(5 Pt 2):1543-1549.
3. WHO: Medical Eligibility Criteria for Contraceptive Use 2008 Update. 2008.
4. Daly CC, Helling-Giese GE, Mati JK, and Hunter DJ: Contraceptive methods and the transmission of HIV: Implications for family planning. Genitourin Med 1994;70(2):110-117.
5. Mauck CK, Callahan MM, Baker J, et al.: The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception 1999;60(1):15-24.
6. Baeten JM, Lavreys L, and Overbaugh J: The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. Clin Infect Dis 2007;45(3):360-369.
7. Hel Z, Stringer E, and Mestecky J: Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev 2010;31(1): 79-97.
8. Heffron R, Donnell D, Rees H, et al.: Use of hormonal contraceptives and risk of HIV-1 transmission: A prospective cohort study. Lancet Infect Dis 2012;12(1):19-26.
9. WHO: Hormonal Contraception and HIV: Technical Statement. 2012.
10. UNAIDS: 09 AIDS epidemic update. http://data.unaids.org/pub/Report/2009/ JC1700-Epi-Update-2009-en.pdf. 2009; http://data.unaids.org/pub/Report/2009/ JC1700-Epi-Update-2009-en.pdf.
11. Ungchusak K, Rehle T, Thammapornpilap P, et al.: Determinants of HIV infection among female commercial sex workers in northeastern Thailand: Results from a longitudinal study. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12(5):500-507.
12. Martin HL Jr, Nyange PM, Richardson BA, et al.: Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis 1998;178(4):1053-1059.
13. Baeten JM, Benki S, Chohan V, et al.: Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 2007;21(13):1771-1777.
14. Morrison CS, Chen PL, Kwok C, et al.: Hormonal contraception and HIV acquisition: Reanalysis using marginal structural modeling. AIDS 2010;24(11):1778-1781.
15. Shelton JD: HIV/AIDS. ARVs as HIV prevention: A tough road to wide impact. Science 2011;334(6063):1645-1646.
16. Marx PA, Spira AI, Gettie A, et al.: Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996;2(10):1084-1089.
17. Smith SM, Baskin GB, and Marx PA: Estrogen protects against vaginal transmission of simian immunodeficiency virus. J Infect Dis 2000;182(3):708-715.
18. Jiang Y, Tian B, Agy MB, Saifuddin M, and Tsai CC: Macaca fascicularis are highly susceptible to an RT-SHIV following intravaginal inoculation: A new model for microbicide evaluation. J Med Primatol 2009;38(Suppl 1):39-46.
19. Pal R, Nuttall J, Galmin L, Weiss D, Chung HK, and Romano J: Characterization of vaginal transmission of a simian human immunodeficiency virus (SHIV) encoding the reverse transcriptase gene from HIV-1 in Chinese rhesus macaques. Virology 2009;386(1):102-108.
20. Salle B, Brochard P, Bourry O, et al.: Infection of macaques after vaginal exposure to cell associated simian immunodeficiency virus. J Infect Dis 2010;202:337-344.
21. Veazey RS, Shattock RJ, Pope M, et al.: Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med. 2003;9(3): 343-346.
22. Miller L, Patton DL, Meier A, Thwin SS, Hooton TM, and Eschenbach DA: Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol 2000;96(3):431-439.
23. Bahamondes L, Trevisan M, Andrade L, et al.: The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. Contraception 2000; 62(1):23-27.
24. Ildgruben AK, Sjoberg IM, and Hammarstrom ML: Influence of hormonal contraceptives on the immune cells and thickness of human vaginal epithelium. Obstet Gynecol 2003; 102(3):571-582.
25. Haase AT: Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011;62:127-139.
26. Pudney J, Quayle AJ, and Anderson DJ: Immunological microenvironments in the human vagina and cervix: Mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod 2005;73(6):1253-1263.
27. Hladik F, Sakchalathorn P, Ballweber L, et al.: Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007;26(2):257-270.
28. Patton DL, Thwin SS, Meier A, et al.: Epithelial cell layer thickness and immune cell populations in the normal human vagina at different stages of the menstrual cycle. Am J Obstet Gynecol 2000;183(4):967-973.
29. Wieser F, Hosmann J, Tschugguel W, et al.: Progesterone increases the number of Langerhans cells in human vaginal epithelium. Fertil Steril 2001;75(6):1234-1235.
30. Wira CR, Fahey JV, Ghosh M, et al.: Sex hormone regulation of innate immunity in the female reproductive tract: The role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am J Reprod Immunol 2011;63(6):544-565.
31. Choe H, Farzan M, Sun Y, et al.: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85(7):1135-1148.
32. Hladik F, Sakchalathorn P, Ballweber L, et al.: Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007;26(2):257-270.
33. Deng H, Liu R, Ellmeier W, et al.: Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996;381(6584): 661-666.
34. Prakash M, Kapembwa MS, Gotch F, and Patterson S: Higher levels of activation markers and chemokine receptors on T lymphocytes in the cervix than peripheral blood of normal healthy women. J Reprod Immunol 2001;52(1-2): 101-111.
35. McKinnon LR, Nyanga B, Chege D, et al.: Characterization of a human cervical CD4 + T cell subset coexpressing multiple markers of HIV susceptibility. J Immunol 2011;187(11):6032-6042.
36. Poonia B, Wang X, and Veazey RS: Distribution of simian immunodeficiency virus target cells in vaginal tissues of normal rhesus macaques: Implications for virus transmission. J Reprod Immunol 2006;72(1-2):74-84.
37. Hirbod T, Kaldensjo T, and Broliden K: In situ distribution of HIV-binding CCR5 and C-type lectin receptors in the human endocervical mucosa. PLoS One 2011;6(9):e25551.
38. Shen R, Richter HE, and Smith PD: Early HIV-1 target cells in human vaginal and ectocervical mucosa. Am J Reprod Immunol 2011;65(3):261-267.
39. Patterson BK, Landay A, Andersson J, et al.: Repertoire of chemokine receptor expression in the female genital tract: Implications for human immunodeficiency virus transmission. Am J Pathol 1998;153(2):481-490.
40. Prakash M, Kapembwa MS, Gotch F, and Patterson S: Oral contraceptive use induces upregulation of the CCR5 chemokine receptor on CD4 (+) T cells in the cervical epithelium of healthy women. J Reprod Immunol 2002;54(1-2):117-131.
41. Sheffield JS, Wendel GD Jr, McIntire DD, and Norgard MV: The effect of progesterone levels and pregnancy on HIV-1 coreceptor expression. Reprod Sci 2009;16(1):20-31.
42. Leroy V, Van de Perre P, Lepage P, et al.: Seroincidence of HIV-1 infection in African women of reproductive age: A prospective cohort study in Kigali, Rwanda, 1988-1992. AIDS 1994;8(7):983-986.
43. Gray RH, Li X, Kigozi G, et al.: Increased risk of incident HIV during pregnancy in Rakai, Uganda: A prospective study. Lancet 2005;366(9492):1182- 1188.
44. Aaby P, Ariyoshi K, Buckner M, et al.: Age of wife as a major determinant of male-to-female transmission of HIV-2 infection: A community study from rural West Africa. AIDS 1996;10(13):1585-1590.
45. Mugo NR, Heffron R, Donnell D, et al.: Increased risk of HIV-1 transmission in pregnancy: A prospective study among African HIV-1-serodiscordant couples. AIDS 2011;25(15): 1887-1895.
46. Jaspan HB, Liebenberg L, Hanekom W, et al.: Immune activation in the female genital tract during HIV infection predicts mucosal CD4 depletion and HIV shedding. J Infect Dis 2011;204(10):1550-1556.
47. Zhang Z, Schuler T, Zupancic M, et al.: Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999;286(5443):1353-1357.
48. Ahmed SM, Al-Doujaily H, Johnson MA, et al.: Immunity in the female lower genital tract and the impact of HIV infection. Scand J Immunol 2001;54(1-2):225-238.
49. Miller CJ and Shattock RJ: Target cells in vaginal HIV transmission. Microbes Infect 2003;5(1):59-67.
50. Hu J, Gardner MB, and Miller CJ: Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000;74(13):6087-6095.
51. Veazey RS, Tham IC, Mansfield KG, et al.: Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: Highly activated memory CD4 (+) T cells are rapidly eliminated in early SIV infection in vivo. J Virol 2000;74(1):57-64.
52. Moore AC, Bixler SL, Lewis MG, Verthelyi D, and Mattapallil JJ: Mucosal and peripheral Lin- HLA-DR + CD11c/123- CD13 + CD14- mononuclear cells are preferentially infected during acute simian immunodeficiency virus infection. J Virol 2012;86(2):1069-1078.
53. Ghanem KG, Shah N, Klein RS, et al.: Influence of sex hormones, HIV status, and concomitant sexually transmitted infection on cervicovaginal inflammation. J Infect Dis 2005; 191(3):358-366.
54. Givan AL, White HD, Stern JE, et al.: Flow cytometric analysis of leukocytes in the human female reproductive tract: Comparison of fallopian tube, uterus, cervix, and vagina. Am J Reprod Immunol 1997;38(5):350-359.
55. White HD, Yeaman GR, Givan AL, and Wira CR: Mucosal immunity in the human female reproductive tract: Cytotoxic T lymphocyte function in the cervix and vagina of premenopausal and postmenopausal women. Am J Reprod Immunol 1997;37(1):30-38.
56. Yeaman GR, White HD, Howell A, Prabhala R, and Wira CR: The mucosal immune system in the human female reproductive tract: potential insights into the heterosexual transmission of HIV. AIDS Res Hum Retroviruses 1998; 14(Suppl 1):S57-62.
57. Saba E, Grivel JC, Vanpouille C, et al.: HIV-1 sexual transmission: Early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol 2010;3:280-290.
58. Edwards JN and Morris HB: Langerhans' cells and lymphocyte subsets in the female genital tract. Br J Obstet Gynaecol 1985;92(9):974-982.
59. Ma Z, Lu FX, Torten M, and Miller CJ: The number and distribution of immune cells in the cervicovaginal mucosa remain constant throughout the menstrual cycle of rhesus macaques. Clin Immunol 2001;100(2):240-249.
60. Spira AI, Marx PA, Patterson BK, et al.: Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 1996;183(1):215-225.
61. Zhang ZQ, Schuler T, Zupancic M, et al.: Sexual transmission and propagation of SIV and HIV in resting and activated CD4 + T cells. Science 1999;286(5443):1353-1357.
62. Collins KB, Patterson BK, Naus GJ, Landers DV, and Gupta P: Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat Med 2000;6(4):475-479.
63. Gupta P, Collins KB, Ratner D, et al.: Memory CD4 (+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system. J Virol 2002;76(19):9868-9876.
64. Pudney J, Quayle AJ, and Anderson DJ: Immunological microenvironments in the human vagina and cervix: Mediators of cellular immunity are concentrated in the cervical transformation zone 1. Biol Reprod 2005;73(6):1253-1263.
65. Wawer MJ, Gray RH, Sewankambo NK, et al.: Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005;191(9):1403-1409.
66. Hladik F and Hope TJ: HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009 2009;6(1):20-28.
67. Morrison CS, Richardson BA, Mmiro F, et al.: Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21(1):85-95.
68. Heffron R, Donnell D, Rees H, et al.: Use of hormonal contraceptives and risk of HIV-1 transmission: A prospective cohort study. Lancet Infect Dis 2012;12(1):19-26.
69. White HD, Crassi KM, Givan AL, et al.: CD3+ CD8 + CTL activity within the human female reproductive tract: influence of stage of the menstrual cycle and menopause. J Immunol 1997;158(6):3017-3027.
70. Saba E, Grivel JC, Vanpouille C, et al.: HIV-1 sexual transmission: Early events of HIV-1 infection of human cervicovaginal tissue in an optimized ex vivo model. Mucosal Immunol 2010;3(3):280-290.
71. Gebhardt T, Whitney PG, Zaid A, et al.: Different patterns of peripheral migration by memory CD4 + and CD8 + T cells. Nature 2011;477(7363):216-219.
72. Mackay LK, Stock AT, Ma JZ, et al.: Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci USA 2012;109:7037-7042.
73. Musey L, Hu Y, Eckert L, Christensen M, Karchmer T, and McElrath MJ: HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. J Exp Med 20 1997;185(2):293-303.
74. Jiang J and Kelly KA: Phenotype and function of regulatory T cells in the genital tract. Curr Trends Immunol 2011;12: 89-94.
75. Keller MJ, Guzman E, Hazrati E, et al.: PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS 2007; 21(4):467-476.
76. Han JH, Kim MS, Lee MY, et al.: Modulation of human betadefensin-2 expression by 17beta-estradiol and progesterone in vaginal epithelial cells. Cytokine 2010;49(2):209-214.
77. Hughes GC, Thomas S, Li C, Kaja MK, and Clark EA: Cutting edge: Progesterone regulates IFN-Alpha production by plasmacytoid dendritic cells. J Immunol 2008;180(4):2029-2033.
78. Genesca M, McChesney MB, and Miller CJ: Depo-provera treatment does not abrogate protection from intravenous SIV challenge in female macaques immunized with an attenuated AIDS virus. PLoS One 2010;5(3):e9814.
79. Blaskewicz CD, Pudney J, and Anderson DJ: Structure and function of intercellular junctions in human cervical and vaginal mucosal epithelia. Biol Reprod 2011;85(1):97-104.
80. Gorodeski GI: Estrogen decrease in tight junctional resistance involves matrix-metalloproteinase-7-mediated remodeling of occludin. Endocrinology 2007;148(1):218-231.
81. Ildgruben AK, Sjoberg IM, and Hammarstrom ML: Influence of hormonal contraceptives on the immune cells and thickness of human vaginal epithelium. Obstet Gynecol 2003;102(3):571-582.
82. Karim Q, Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329(5996): 1168-1174.